Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Regeneron Pharmaceuticals, Inc ×

Regeneron Pharmaceuticals, Inc

This funder is selected. Its supporting articles are shown below.

Regeneron Pharmaceuticals, Inc1

Articles mentioning Regeneron Pharmaceuticals, Inc

1 articles · page 1 of 1

546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC)

jitc · abstract · 2025-11-04 · 1 matching annotations

85.4%

Regeneron Pharmaceuticals, Inc OPEN Health Communications sarilumab ubamatamab

…ced CRS is ongoing.Acknowledgements This study was supported by Regeneron Pharmaceuticals, Inc. Medical writing assistance was provided by Joe Bolton, of Ober…

Browse funders

Regeneron Pharmaceuticals, Inc

Articles mentioning Regeneron Pharmaceuticals, Inc

546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC)